+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID04915248

Evaluation of Daratumumab Combined with Bortezomib and Dexamethasone for Relapsed or Refractory Plasmablastic Lymphoma

Led by Fondazione Italiana Linfomi - ETS · Updated on 2026-09-09

28

Participants Needed

18

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and activity of a combination treatment using daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory plasmablastic lymphoma. This phase II, open-label, single-arm trial plans to enroll around 28 patients across multiple centers. Patients must have a confirmed diagnosis with at least 5% CD38 expression and have relapsed or refractory disease after prior chemotherapy treatments. The treatment begins with an induction phase consisting of one cycle of daratumumab alone, followed by eight cycles combining daratumumab with bortezomib and dexamethasone every 21 days. Patients showing stable disease or better after induction enter a maintenance phase of up to six cycles of daratumumab alone, administered every 28 days. Treatment may stop early if disease progresses, side effects are unacceptable, or consent is withdrawn. Participants undergo baseline assessments and provide biopsy samples for central review during or after the study. Researchers monitor adverse events throughout treatment and for 30 days after the last dose. The main outcome measured is the overall response rate at 30 months, along with progression-free survival, overall survival, duration of response, and treatment-related side effects. The total study duration is about five years, allowing thorough evaluation and safety monitoring.

CONDITIONS

Brief Title

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

Research Team

M

Marina Cesaretti, Dr.ssa

L

Lorenza Randi, Dr.ssa

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here